TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy.
Adjuvant
Anti-PD-1
Checkpoint inhibition
Melanoma
RFS
Tumor mutational burden
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
04
11
2021
accepted:
31
01
2022
pubmed:
23
2
2022
medline:
18
2
2023
entrez:
22
2
2022
Statut:
ppublish
Résumé
High tumor mutational burden (TMB) is associated with a favorable outcome in metastatic melanoma patients treated with immune checkpoint inhibitors. However, data are limited in the adjuvant setting. As BRAF mutated patients have an alternative with targeted adjuvant therapy, it is important to identify predictive factors for relapse and recurrence-free survival (RFS) in patients receiving adjuvant anti-PD-1 antibodies. We evaluated 165 melanoma patients who started adjuvant anti-PD-1 antibody therapy at our center between March 2018 and September 2019. The initial tumor stage was assessed at the beginning of therapy according to the 8th edition of the AJCC Cancer Staging Manual. Tumor and normal tissue of the high-risk stages IIIC/D/IV were sequenced using a 700 gene NGS panel. The tumor stages at the beginning of adjuvant anti-PD-1 therapy were as follows: N = 80 stage IIIA/B (48%), N = 85 stage IIIC/D/IV (52%). 72/165 patients (44%) suffered a relapse, 44/72 (61%) with only loco regional and 28/72 (39%) with distant metastases. Sequencing results were available from 83 to 85 patients with stage IIIC/D/IV. BRAF mutation status (HR 2.12, 95% CI 1.12-4.08; p = 0.022) and TMB (HR 7.11, 95% CI 2.19-23.11; p = 0.001) were significant and independent predictive factors for relapse-free survival (RFS). BRAF mutation status and TMB were independent predictive factors for RFS. Patients with BRAF V600E/K mutation and TMB high had the best outcome. A classification based on BRAF mutation status and TMB is proposed to predict RFS in melanoma patients with adjuvant anti-PD-1 therapy.
Sections du résumé
BACKGROUND
BACKGROUND
High tumor mutational burden (TMB) is associated with a favorable outcome in metastatic melanoma patients treated with immune checkpoint inhibitors. However, data are limited in the adjuvant setting. As BRAF mutated patients have an alternative with targeted adjuvant therapy, it is important to identify predictive factors for relapse and recurrence-free survival (RFS) in patients receiving adjuvant anti-PD-1 antibodies.
METHODS
METHODS
We evaluated 165 melanoma patients who started adjuvant anti-PD-1 antibody therapy at our center between March 2018 and September 2019. The initial tumor stage was assessed at the beginning of therapy according to the 8th edition of the AJCC Cancer Staging Manual. Tumor and normal tissue of the high-risk stages IIIC/D/IV were sequenced using a 700 gene NGS panel.
RESULTS
RESULTS
The tumor stages at the beginning of adjuvant anti-PD-1 therapy were as follows: N = 80 stage IIIA/B (48%), N = 85 stage IIIC/D/IV (52%). 72/165 patients (44%) suffered a relapse, 44/72 (61%) with only loco regional and 28/72 (39%) with distant metastases. Sequencing results were available from 83 to 85 patients with stage IIIC/D/IV. BRAF mutation status (HR 2.12, 95% CI 1.12-4.08; p = 0.022) and TMB (HR 7.11, 95% CI 2.19-23.11; p = 0.001) were significant and independent predictive factors for relapse-free survival (RFS).
CONCLUSION
CONCLUSIONS
BRAF mutation status and TMB were independent predictive factors for RFS. Patients with BRAF V600E/K mutation and TMB high had the best outcome. A classification based on BRAF mutation status and TMB is proposed to predict RFS in melanoma patients with adjuvant anti-PD-1 therapy.
Identifiants
pubmed: 35192052
doi: 10.1007/s00432-022-03939-w
pii: 10.1007/s00432-022-03939-w
pmc: PMC9931777
doi:
Substances chimiques
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Adjuvants, Immunologic
0
BRAF protein, human
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
833-840Informations de copyright
© 2022. The Author(s).
Références
Eur J Cancer. 2014 Oct;50(15):2668-76
pubmed: 25070294
Genome Biol. 2016 Jun 06;17(1):122
pubmed: 27268795
Cell. 2017 Jan 26;168(3):542
pubmed: 28129544
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
J Clin Oncol. 2018 Dec 10;36(35):3441-3449
pubmed: 30343620
J Immunother Cancer. 2019 Jul 12;7(1):180
pubmed: 31300034
Lancet Oncol. 2018 Nov;19(11):1480-1492
pubmed: 30361170
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
J Clin Oncol. 2012 Jul 10;30(20):2522-9
pubmed: 22614978
Cancers (Basel). 2020 Feb 26;12(3):
pubmed: 32110946
Lancet Oncol. 2020 Mar;21(3):358-372
pubmed: 32007138
Br J Cancer. 2016 Mar 29;114(7):801-8
pubmed: 26924424
N Engl J Med. 2017 Nov 9;377(19):1824-1835
pubmed: 28891423
Int J Cancer. 2019 Feb 15;144(4):848-858
pubmed: 30238975
J Clin Oncol. 2020 Nov 20;38(33):3925-3936
pubmed: 32946353
N Engl J Med. 2017 Nov 9;377(19):1813-1823
pubmed: 28891408
Nature. 2002 Jun 27;417(6892):949-54
pubmed: 12068308
J Clin Oncol. 2011 Apr 1;29(10):1239-46
pubmed: 21343559
Lancet Oncol. 2020 Nov;21(11):1465-1477
pubmed: 32961119
N Engl J Med. 2018 May 10;378(19):1789-1801
pubmed: 29658430
PLoS One. 2014 Feb 20;9(2):e89218
pubmed: 24586605
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
Br J Cancer. 2014 Jul 15;111(2):292-9
pubmed: 24918823
J Dtsch Dermatol Ges. 2020 Jun;18(6):659
pubmed: 32519496
Lancet. 2020 May 16;395(10236):1558-1568
pubmed: 32416781
Eur J Cancer. 2016 Aug;63:201-17
pubmed: 27367293
JAMA. 2016 Apr 19;315(15):1600-9
pubmed: 27092830
Nat Methods. 2018 Aug;15(8):591-594
pubmed: 30013048
Br J Dermatol. 2013 Nov;169(5):1049-55
pubmed: 23855428
Ann Surg Oncol. 2012 Dec;19(13):4314-21
pubmed: 22772867
Br J Dermatol. 2014 Jul;171(1):108-14
pubmed: 24602025
PLoS Med. 2014 Feb 18;11(2):e1001604
pubmed: 24558354
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254
Ann Surg Oncol. 2018 Aug;25(8):2105-2110
pubmed: 29850954
Clin Cancer Res. 2019 Feb 1;25(3):1063-1069
pubmed: 30045933